--- title: "Kairos Pharma announces Bayer collaboration to test ENV-105 with XOFIGO" url: "https://aibio.space/news/kairos-pharma-announces-bayer-collaboration-test-env-105-xofigo/" publisher: "aibio.space (Biotech Investor Relations News)" date: "2026-07-22" section: "Company Updates" tickers: "AMEX:KAPA" source: "https://www.sec.gov/Archives/edgar/data/1962011/000149315226034185/ex99-1.htm" summary: "The collaboration will evaluate ENV-105 with Bayer's XOFIGO (radium-223 dichloride) in metastatic castration-resistant prostate cancer involving bone, and" --- By the aibio.space news desk. Sources - [Kairos Pharma, Ltd. 8-K (2026-07-22)](https://www.sec.gov/Archives/edgar/data/1962011/000149315226034185/ex99-1.htm) - [Kairos Pharma, Ltd. 10-K (2026-03-31): business](https://www.sec.gov/Archives/edgar/data/1962011/000149315226014159/form10-k.htm) - [Kairos Pharma, Ltd. financial data (SEC XBRL)](https://www.sec.gov/Archives/edgar/data/1962011/000149315226014159/) [KAPA](https://aibio.space/companies/kairos-pharma/) 2026-07-22 # Kairos Pharma announces Bayer collaboration to test ENV-105 with XOFIGO Tickers [KAPA](https://aibio.space/companies/kairos-pharma/) The collaboration will evaluate ENV-105 with Bayer's XOFIGO (radium-223 dichloride) in metastatic castration-resistant prostate cancer involving bone, and the company cites a $570M to $1.3B addressable global market. ## Key facts - **Company**: Kairos Pharma, Ltd. (AMEX: KAPA) - **News type**: Company Updates - **Primary source**: [Kairos Pharma, Ltd. 8-K (2026-07-22)](https://www.sec.gov/Archives/edgar/data/1962011/000149315226034185/ex99-1.htm) *The eyepieces of a laboratory microscope. CC0, via rawpixel. The picture shows the field, not the companies named.* Kairos Pharma, Ltd. (NYSE American: [KAPA](https://aibio.space/companies/kairos-pharma/)) announced a strategic collaboration with Bayer to evaluate its lead antibody, ENV-105 (carotuximab), in combination with Bayer's XOFIGO (radium-223 dichloride) in metastatic castration-resistant prostate cancer (mCRPC) involving bone. The announcement was made in a press release dated July 22, 2026, filed as Exhibit 99.1 to a [Form 8-K](https://www.sec.gov/Archives/edgar/data/1962011/000149315226034185/ex99-1.htm). The release describes ENV-105 as a first-in-class CD105/BMP signaling inhibitor. It does not state the start date, the size or the financial terms of the collaboration. ## The rationale Kairos says CD105 is upregulated in response to standard androgen receptor inhibition and in response to ionizing radiation, where it drives pro-survival BMP-SMAD signaling pathways underlying therapy resistance. The company states that previously published work demonstrated the efficacy of ENV-105 in radiation sensitization in prostate cancer preclinical models. In its view, targeting CD105 with ENV-105 re-sensitizes resistant tumors and may extend the duration and depth of response to XOFIGO's targeted alpha therapy. Chief Executive Officer John Yu, M.D., said: "Drug resistance remains one of the greatest challenges in advanced prostate cancer, and XOFIGO, like many standard-of-care therapies, can lose efficacy over time." Neil Bhowmick, Ph.D., Chief Scientific Officer and Principal Investigator, said that "CD105's role as a central resistance mechanism validated now across multiple drug classes makes this collaboration scientifically compelling and clinically timely, given XOFIGO's recent Phase III momentum." ## XOFIGO and the company's data The release describes XOFIGO as the first and only FDA-approved alpha-emitting radiopharmaceutical for mCRPC with symptomatic bone metastases. It says XOFIGO is advancing through additional combination studies, including the Phase III PEACE-3 trial, which demonstrated a 24% reduction in mortality risk when combined with enzalutamide (HR 0.76; p=0.009). Kairos points to its own clinical work as well. The release says that last year the company announced positive interim efficacy data from its Phase 2 trial, showing median progression-free survival of more than 13 months, and that those data were presented at the 2025 ESMO Congress in Berlin. The release's headline cites an 86% clinical benefit rate for ENV-105 in resistant mCRPC. The company's current ENV-105 programs include a Phase 1 trial in EGFR-driven non-small cell lung cancer and a Phase 2 trial in castrate resistant prostate cancer. ## Company background In its annual report on Form 10-K, filed March 31, 2026, Kairos describes itself as a clinical-stage biopharmaceutical company developing antibodies and small molecules for prostate cancer, lung cancer, breast cancer and glioblastoma. Its proprietary technologies are licensed from Cedars-Sinai Medical Center. The company says ENV 105 targets endoglin, also known as CD105, and that the Enviro Therapeutics, Inc. acquisition, announced in June 2021, added the pipeline. ## Financial position SEC XBRL data show research and development expense of $2.1 million for 2025, compared with $414,000 for 2024. The net loss was $5.4 million for 2025 and $2.6 million for 2024, and cash flow from operations was negative $3.4 million in 2025 and negative $4.0 million in 2024. Year-end 2024 cash and cash equivalents were $1.3 million. The release does not state a cash runway. ## What the release does not show The release does not state the start date, size or financial terms of the collaboration, so it describes an intention, not a finished arrangement. The PEACE-3 result it cites is for XOFIGO plus enzalutamide, not for ENV-105. The 86% clinical benefit rate and the 13-month progression-free survival come from an ongoing Phase 2 trial, with no patient numbers, p-values or confidence intervals in the release. The 10-K, for its part, reports a clinical benefit rate of 62% in a Phase 2 trial of heavily pre-treated patients, and says ENV105 alone has shown no clinical benefit in preclinical and earlier clinical findings. The CEO's reference to a strong safety profile comes with no safety data. Kairos has no approved product: its 10-K says none of its candidates has been approved as safe or effective by the FDA or any comparable foreign regulator. The 2025 net loss was $5.4 million and cash flow from operations was negative $3.4 million, and the release does not state a cash runway. [Report an error](https://aibio.space/reputation/#correction) ## Companies in this story KAPA Kairos Pharma, Ltd. AMEX ยท United States Open the starter desk ## More in Company Updates Company Updates ### [PTC reports third-quarter 2026 revenue of $358 million and raises product guidance](https://aibio.space/news/ptc-reports-third-quarter-2026-revenue-358-million-raises-product/) Oct 29, 2026 Company Updates ### [Processa clears VT-7208 CSU IND and names a new executive chair](https://aibio.space/news/processa-clears-vt-7208-csu-ind-names-new-executive-chair/) Oct 29, 2026 Company Updates ### [Kiora in-licenses late-stage KIO-401 for retinal artery occlusion](https://aibio.space/news/kiora-licenses-late-stage-kio-401-retinal-artery-occlusion/) Oct 29, 2026 --- Source page: https://aibio.space/news/kairos-pharma-announces-bayer-collaboration-test-env-105-xofigo/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Kairos Pharma announces Bayer collaboration to test ENV-105 with XOFIGO", 2026-07-22, https://aibio.space/news/kairos-pharma-announces-bayer-collaboration-test-env-105-xofigo/